In development: Guidance, quality standards and advice

Skip to filters Skip to results

Showing 226 to 250 of 434

Sort by

Guidance, NICE advice and quality standards in development
Title	Type	Expected publication date
Masitinib with riluzole for treating amyotrophic lateral sclerosis [ID6257]	Technology appraisal guidance	TBC
Mavacamten for treating symptomatic non-obstructive hypertrophic cardiomyopathy [ID6523]	Technology appraisal guidance	TBC
Melanoma (metastatic) - talimogene laherparepvec [ID508]	Technology appraisal guidance	28 September 2016
Melphalan chemosaturation with percutaneous hepatic artery perfusion and hepatic vein isolation for primary or metastatic cancer in the liver	Interventional procedures guidance	TBC
Mental health guidelines	NICE guideline	TBC
Mepolizumab for maintenance treatment of uncontrolled chronic obstructive pulmonary disease with raised blood eosinophils ID1237	Technology appraisal guidance	6 August 2026
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)	NICE guideline	2 December 2026
Mezigdomide with dexamethasone and carfilzomib for treating relapsed or refractory multiple myeloma after at least 1 line of treatment [ID6513]	Technology appraisal guidance	TBC
Middle meningeal artery embolisation for chronic subdural haematomas	Interventional procedures guidance	TBC
Mirdametinib for treating symptomatic inoperable plexiform neurofibromas in people 2 years and over with neurofibromatosis type 1 [ID6618]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]	Technology appraisal guidance	TBC
Mirvetuximab soravtansine for treating folate receptor alpha-positive platinum-resistant advanced epithelial ovarian, fallopian tube or primary peritoneal cancer [ID6442]	Technology appraisal guidance	12 March 2026
Mozafancogene autotemcel for treating Fanconi anaemia in people 1 to 17 years [ID12203]	Technology appraisal guidance	TBC
MRI-guided focused ultrasound thalamotomy for treatment-resistant essential tremor	Interventional procedures guidance	TBC
MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]	Technology appraisal guidance	TBC
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy [ID6369]	Technology appraisal guidance	TBC
Navepegritide for treating achondroplasia in people 2 to 15 years [ID6538]	Technology appraisal guidance	TBC
Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]	Technology appraisal guidance	TBC
Nemolizumab for treating prurigo nodularis [ID6451]	Technology appraisal guidance	TBC
Neonatal infection: antibiotics for prevention and treatment - risk factors for early onset neonatal infection	NICE guideline	13 May 2026
Nerandomilast for treating idiopathic pulmonary fibrosis or progressive pulmonary fibrosis ID6446	Technology appraisal guidance	TBC
Neuro-Cells stem-cell treatment for traumatic spinal cord injury [ID6588]	Technology appraisal guidance	TBC
Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib [ID858]	Technology appraisal guidance	28 June 2017
Nipocalimab for treating generalised myasthenia gravis [ID6562]	Technology appraisal guidance	TBC
Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy (review of TA673) [ID6403]	Technology appraisal guidance	TBC

Results per page

10
25
50
All